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Background: Assessing inflammatory activity is useful in the management of persistent symp-
tomatic sarcoidosis patients. 18F-FDG PET (PET) has been shown to be a sensitive technique to
assess inflammatory activity in sarcoidosis. The aim of this study was to evaluate whether the
severity of pulmonary involvement is associated with PET activity in persistent symptomatic
sarcoidosis patients.
Methods: Over a 5-year period, relevant clinical data including laboratory and lung function
test results were gathered from the medical records of 95 sarcoidosis patients with persistent
disabling symptoms who underwent both a PET and HRCT. HRCT scans were classified using
a semiquantitative scoring system and PET findings as positive or negative, respectively.
Results: PET was positive in 77/95 patients, of whom 56 demonstrated pulmonary
PET-positivity. HRCT scores were high (7.1  3.6) in patients with positive pulmonary PET find-
ings (n Z 56) compared to patients with negative pulmonary PET findings (n Z 39; 3.0  2.9;
p < 0.001). DLCO (65  20% predicted) and FVC (85  24% predicted) were low in patients with
pulmonary PET-positivity versus those with negative pulmonary PET findings (79  16% pre-
dicted; p Z 0.001 and 96  22% predicted; p Z 0.044, respectively). Interestingly, out of
the 26 patients with fibrotic changes, 22 (85%) had positive pulmonary PET findings, of whomealth, Medicine and Life Sciences, UNS 40 room 4.550, University Maastricht, PO Box 3100, 6202 NC
1 43 3882087; fax: þ31 84 2234007.
htuniversity.nl (M. Drent).
2 Elsevier Ltd. All rights reserved.
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440 R.L.M. Mostard et al.18/22 (82%) showed extrathoracic PET-positive lesions and 16/22 (73%) showed signs of sero-
logical inflammation.
Conclusions: The severity of the pulmonary involvement, assessed by HRCT features and lung
function parameters, appeared to be associated with PET activity in sarcoidosis. The majority
of patients with fibrotic changes demonstrated inflammatory activity at pulmonary and extra-
thoracic sites.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multisystemic disease characterized by
activity of cellular immunity with formation of non-
caseating granuloma in various organ systems.1 The
majority of deaths from sarcoidosis results from respiratory
failure and no universal definition exists for what consti-
tutes ‘active’ pulmonary disease. It is therefore important
to accurately assess pulmonary involvement. The reliable
detection of changes in pulmonary disease severity in
sarcoidosis by using chest radiography and lung function
testing has proved problematic.2 Forced vital capacity
(FVC) and the diffusion capacity for carbon monoxide
(DLCO) have been regarded as the most accurate pulmo-
nary function measures of pulmonary involvement in
sarcoidosis and deterioration is regarded as an indicator of
disease activity in sarcoidosis.2,3 However, assessment of
disease activity through lung function tests requires
evidence of progression between two measurements and so
does not reflect the current status. Moreover, lung function
testing cannot distinguish between reversible granuloma-
tous lesions and irreversible fibrotic changes, and corre-
lates only modestly with the level of dyspnea reported by
patients.3,4 Although chest radiography (CXR) is most often
the first diagnostic imaging study for assessment of
pulmonary involvement in sarcoidosis, the radiographic
score (stages 0eIV) possesses limited value in predicting
inflammatory activity.1,5e7 It is not always clear whether
respiratory symptoms in patients with sarcoidosis are
a result of irreversible organ damage or due to ongoing
inflammatory activity or both. Hence, in patients with more
severe disease, including radiographic stage IV, it is often
difficult to differentiate between these two situations.
The high-resolution CT (HRCT) uses short scanning times
and thin collimation, making it possible to demonstrate
lung parenchyma in detail and to detect abnormal changes
of the lung parenchyma at an early stage.8 The presence
and extent of parenchymal abnormalities on HRCT has been
found to correlate with respiratory functional impairment
in sarcoidosis.6,9e13 However, HRCT is a morphological
imaging technique that provides only indirect information
on the underlying metabolic changes. Due to pre-existing
major abnormalities, HRCT features are therefore
frequently of limited value for the assessment of inflam-
matory activity in sarcoidosis patients with pulmonary
fibrosis, since it is not possible to differentiate between
fibrotic and residual granulomatous components in the
parenchymal consolidations.
18F-FDG PET/CT (PET) is used to detect high glucose
metabolism and has been shown to be useful for the
assessment of inflammatory activity in sarcoidosis.14e18Recently, elevated serological inflammatory markers were
found to be associated with PET-positivity.19 To date, only
limited information is available about the relationship
between morphological and functional pulmonary abnor-
malities, and metabolic changes as measured by PET find-
ings in sarcoidosis patients.
The aim of the present study was to evaluate whether
the severity of pulmonary involvement as assessed by HRCT
features and lung function parameters is associated with
PET activity in sarcoidosis.Materials and methods
We reviewed the medical records of all sarcoidosis patients
referred to the interstitial lung disease service (ild care
team) of the department of Respiratory Medicine at the
Maastricht University Medical Centre (Maastricht, The
Netherlands), a tertiary referral center, between June 2005
and September 2010. During this period, all sarcoidosis
patients who were referred with unexplained disease
related symptoms that persisted for at least one year
(n Z 106), underwent laboratory testing, lung function
testing, a HRCT scan, and a PET scan. The indication for
performing the PETwas the presence of unexplained disease
related disabling symptoms that persisted for at least one
year. Persistent disabling symptoms were defined as the
presence of more than one symptom that had substantial
influence on quality of life, and that could not be explained
with the results of routine investigations, including the
absence of lung functional or chest radiographic deteriora-
tion. These symptoms included fatigue (Fatigue Assessment
Scale [FAS] 22),20 symptoms compatible with small fiber
neuropathy (SFN; SFN Screenings List [SFNSL] score 11),21
arthralgia and/or muscle pain, dyspnea (MRC dyspnea
scale 3), exercise intolerance or coughing. Laboratory and
lung function testing were performed within a 2-week
interval before or after the HRCT. PET scans were made
within a 3-months interval before or after the HRCT, without
changing the therapy during this period. In all cases,
patients had a clinical presentation compatible with
sarcoidosis. The diagnosis was confirmed histologically,
demonstrating noncaseating epitheloid cell granulomas, in
most cases (75%). Histological evidence of granulomatous
disease in more than one organ was present in 60% of the
patients. In the patients without histological evidence (25%),
the diagnosis of sarcoidosis was based on consistent clinical
features and bronchoalveolar fluid analysis, in accordance
with the WASOG guidelines.1 Moreover, 12 patients (13%)
initially presented with Lo¨fgren’s syndrome, and in those
cases we did not obtain a biopsy as it was not of clinical
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ciated with PET-positive findings were excluded. Therefore,
five patients with common variable immunodeficiency
(CVID), five patients with malignancy and one patient with
both rheumatoid arthritis and amyloidosis were excluded.
After exclusion for these criteria, 95 patients were selected.
The study protocol was approved by the Medical Research
Ethics Committee of our institution.
Laboratory tests
Serum angiotensin-converting enzyme (ACE) was measured
by colorimetric method (cat. no. FU 116; Fujirebio Inc.),
the reference interval was 9e25 U L1. Serum levels of
soluble interleukin-2 receptor (sIL-2R) were analyzed in
commercially available Diaclone ELISA kits (Sanquin,
Amsterdam, The Netherlands) and considered elevated if
>3154 pg mL1. Serum levels of neopterin were evaluated
by a competitive ELISA (IBL; Hamburg, Germany). Serum
levels were considered elevated if >2.5 ng mL1.
Results for combined serological inflammatory marker
testing (ACE, sIL-2R and neopterin) were considered posi-
tive if at least one of the serological inflammatory markers
was elevated.
C-reactive protein (CRP) was measured using a turbidi-
metric method performed using the Beckman synchron CX-7
system (kit 465231; Mijdrecht, The Netherlands. The
detection limit for CRP was 2 mg mL1, with a normal range
of 2e9 mg mL1.
Chest radiography
According to the Scadding radiographic staging system, five
stages of radiographic abnormality (0eIV) were
recognized.1
Lung function tests
FVC was measured with a pneumotachograph (Masterlab,
Jaeger, Wu¨rzburg, Germany). DLCO was measured by the
single-breath method (Masterlab, Jaeger, Wu¨rzburg,
Germany). Values were expressed as a percentage of pre-
dicted values.22
Imaging
Thin-section scans with 1-mm collimation were obtained at
10-mm intervals through the chest (Somaton Plus, Siemens,
Erlangen, Germany). The scanning parameters included
137 kVP, 255 mA, and 1-s scanning time. Both mediastinal
(with 400 HU, level 40 HU) and lung (width 1600 HU, level
800 HU) window images were obtained. Scans were recon-
structed with a high-frequency reconstruction algorithm.
A whole body 18F-FDG PET/CT scan was performed using
a Gemini PET-CT (Philips Medical Systems) scanner with
time of-flight (TOF) capability, together with a 64-slice
Brilliance CT scanner. Patients were fasting for at least
6 h before the examination. In all patients blood glucose
was measured to ensure that the blood glucose was below
10 mmol L1. 18F-FDG (GE Health, Eindhoven, The
Netherlands) was injected intravenously and followed byphysiologic saline (10 mL). The injected total activity of
FDG depended on the weight of the patient. Mean injected
dose was: 200 MBq. After a resting period of 45 min (time
needed for uptake of FDG) PET and CT images were
acquired from the head to the feet. A low dose CT-scan was
performed without intravenous contrast and was used for
attenuation correction of the PET images. The PET images
were acquired in 5-min bed positions. The complete PET
data set was reconstructed iteratively with a reconstruc-
tion increment of 5 mm to provide isotropic voxel.
Image analysis
An experienced thoracic radiologist (JV), blinded to the
patient’s clinical history and to the PET findings, classified
the scans of both lungs using a semiquantitative HRCT
scoring system that has been described by Oberstein et al.13
and that has been used in previous studies of our group.6
This scoring system is explained in detail in Table 1.
Separately, the presence of signs of fibrosis (architec-
tural distortion as shown by distortion of the airways and
blood vessels, irregular distortion of the septal and intra-
lobular lines, retraction of the hila and fissures, cystic
formation and traction bronchiectasis)23,24 was evaluated.
All PET were interpreted by an experienced nuclear
medicine physician (MvK), blinded to the patient’s clinical
history and to the HRCT findings. PET findings in the lungs,
lymph nodes, or other soft tissues or bones were scored as
either positive or negative. A positive PET scan interpre-
tation was performed visually, with a threshold standard-
ized uptake value (SUVmax) 2.5. 18F-FDG uptake was
quantified by drawing a region of interest around the area
of pathology of the co-registered transaxial slice. SUVmax
was calculated as the maximal pixel activity within the
region of interest. The degree of increased metabolic
activity in the pulmonary parenchyma needed to be higher
than the mediastinal background.
In a next step in a consensus meeting between radiologist
and nuclear medicine physician, in the patients with
pulmonary PET-positivity, the area of most intensive
thoracic 18F-FDG uptakewas identified and theHRCT pattern
in this regionwas assessed. This predominant HRCTsubstrate
of thoracic 18F-FDG uptake was classified as one of the items
included in the HRCT score. Inter-reader reliability of the
total HRCT score and of the simple PET classification system
we used proved to be very good, as reported in previous
studies with the same observers (weighted kappa 0.99 and
1.00, respectively).6,19 Accordingly, in the present study,
observation by a single radiologist and a single nuclear
physician was regarded to be sufficient.
Statistical procedure
Statistical analyses were performed using SPSS, version
15.0 for Windows. Differences were tested for statistical
significance using the Student’s t-test for independent
samples in case of continuous variables or chi-square test in
case of categorical variables. A p value of <0.05 (two sided)
was considered to indicate statistical significance.
Receiver operating characteristic (ROC) curves were
constructed to evaluate the ability of the total HRCT score
Table 1 Definition of abnormal high-resolution computed tomography (HRCT) findings in sarcoidosis, adapted from Oberstein
et al.,13 visual score.
Lung volume affecteda
No lesions: 0 <33%:1 <66%:2 >66%:3
Typical patterns of parenchymal involvement
BVB
PC
ND
LS
Pathological findingsb
None: 0 Minor:1 Moderate: 2 Pronounced:3
PL
LN
BVB: thickening or irregularity of the bronchovascular bundle; PC: parenchymal consolidation (including groundglass opacifications); ND:
intraparenchymal nodules; LS: septal and nonseptal lines; PL: focal pleural thickening; LN: enlargement of the mediastinal lymph nodes.
The total score is obtained by adding up the individual scores (BVB, ND, LS, PC, LN, and PL).
a The lung volume affected is quantified by a visual score: 0Z no lesions found; 1Z up to 33%; 2Z up to 66%; and 3Z more than 66%
of the volume affected.
b The PL and the enlargement of the LN (with a short axis of 1 cm or more considered enlarged) were quantified: 0Z no pathological
findings; 1 Z minor; 2 Z moderate; and 3 Z pronounced changes.
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positive results. Areas under the curve (AUC) values with
95% confidence intervals (CI) were used to quantify and
visualize the strength of the association.
Results
In Table 2, relevant demographic and clinical characteristics of
the studied sarcoidosis patients (87 Caucasians, five of African
origin and three of Asian origin) categorized by absence
(nZ39: 41%) or presence (nZ 56: 59%) of positivePETfindings
in the pulmonary parenchyma are summarized. The median
SUVmax in the PET-positive patients was 7.0 (2.5e24.2).
Treatment at the time of PET scanning was not different
between patients with positive PET findings in the pulmonary
parenchyma compared with those who had negative PET
findings in the pulmonary parenchyma (see also Table 2).
Forty patients (71%) in the pulmonary PET-positive group
demonstrated one or more extrathoracic lesions. In the
pulmonary PET-negative group, 21 patients had extra-
thoracic positive PET findings. Extrathoracic positive PET
findings in the sarcoidosis patients categorized by absence
or presence of positive PET findings in the pulmonary
parenchyma are shown in Table 3.
Relation between morphological and metabolic
changes
Association between HRCT (sub)scores and pulmonary
PET-positivity
ThetotalHRCTscoreaswell as the subscores of the56patients
with pulmonary PET-positivity was high compared with the 39
patients with pulmonary PET-negativity (see Table 4).
ROC curve results for the association between the total
HRCT score and pulmonary PET-positive results are pre-
sented in Fig. 1. The AUC was 0.81 (95% CI: 0.73e0.90).The AUCs of the various HRCT patterns as included in the
HRCT score are presented in Table 5. All patients with
a total HRCT score >9 (n Z 17) had positive PET findings
and all patients with a total HRCT score >10 (n Z 16) had
pulmonary positive PET findings. None of the patients with
a total HRCT score of 0 points (nZ 11) had pulmonary PET-
positive findings, nevertheless five of them had extra-
thoracic positive PET findings and two of them showed
increased serological inflammatory markers.
Predominant HRCT pattern on area of most intensive
thoracic 18F-FDG uptake
The predominant HRCT pattern on the area of most inten-
sive thoracic 18F-FDG uptake were parenchymal consolida-
tions in 48%, lymph nodes in 25%, intraparenchymal nodules
in 21%, septal and nonseptal lines in 4% and pleural thick-
ening in 2% of the patients, respectively.
Presence of fibrosis on HRCT
Signs of fibrosis on HRCT were present in 26 patients. The
majority (22/26; 85%) of these patients showed positive
pulmonary PET findings. Median SUVmax in these patients
was 7.1 (3.1e16.2). Extrathoracic PET-positive findings
were present in 18 (82%) and positive combined serological
inflammatory marker testing in 16 (73%), respectively. An
example of pulmonary PET-positivity in a sarcoidosis
patient with fibrotic changes on HRCT is shown in Fig. 2.Relation between functional tests and metabolic
changes
Association between lung function and pulmonary PET-
positivity
In the PET-positive patient group, DLCO was lower in
patients with pulmonary PET-positivity (65  20% pre-
dicted) versus the patients with exclusively extrapulmonary
Table 3 Extrathoracic and mediastinal positive PET find-
ings in the sarcoidosis patients categorized by absence or
presence of positive PET findings in the pulmonary
parenchyma.
Extrathoracic and
mediastinal positive
PET findings
Pulmonary
parenchyma
PET  patients
(n Z 39; CXR
0eI/IIeIV: 29/10)
Pulmonary
parenchyma
PET þ patients
(n Z 56; CXR
0eI/IIeIV: 17/39)
Mediastinal lymph
nodes
15 (39%) 43 (77%)
Peripheral lymph
nodes
18 (46%) 38 (68%)
Liver 0 9 (16%)
Spleen 2 (5%) 14 (25%)
Parotid glands 4 (10%) 13 (23%)
Skin 1 (3%) 1 (2%)
Bone 7 (18%) 16 (29%)
Central nervous
system
0 1 (2%)
Data are presented as absolute numbers with percentages in
parentheses; PET: positron emission tomography; n Z number;
CXR: chest X-ray.
Table 2 Demographic and clinical characteristics of the sarcoidosis patients categorized by absence or presence of positive
PET findings in the pulmonary parenchyma.
Pulmonary parenchyma
PETepatients (n Z 39)
Pulmonary parenchyma
PET þ patients (n Z 56)
p value
age (yrs) 44 (22e72) 48 (24e76) NS
sex (male) 22 (56%) 33 (59%) NS
time since diagnosis (yrs) 2 (1e20) 2 (1e21) NS
Therapy total number (%) 9 (23%) 17 (30%) NS
1/2/3/4 4/1/4/0 9/6/1/1 NS
ACE (9e25 U/L) 15 (1e35) 19 (3e60) 0.030
sIL-2R (240e3154 pg/mL) 2028 (518e9662) 3451 (1191e15000) 0.004
Neopterin (<2.5 ng/mL) 1.7 (0.8e2.8) 3.0 (0.7e18.2) 0.004
CRP (2e9 mg/mL) 4 (1e80) 6 (1e70) NS
CXR stage 0/I 22/7 8/9 0.016
CXR stage II/III/IV 2/5/3 11/5/23 NS
FVC total (% pred) 96  22 85  24 0.044
CXR 0eI 98  22 105  11 NS
CXR IIeIV 91  24 80  20 NS
DLCO total (% pred) 79  16 65  20 0.001
CXR 0eI 81  16 76  19 NS
CXR IIeIV 71  16 60  19 NS
RFI total 21/39 (54%) 45/56 (81%) 0.008
CXR 0eI 14/29 (48%) 11/17 (65%) NS
CXR IIeIV 7/10 (70%) 34/39 (87%) NS
Data are presented as median with range in parentheses; mean  SD; absolute numbers or percentages if appropriate. PET: positron
emission tomography; -: negative; þ: positive; n:number; yrs: years; NS: not significant; therapy total: total number of patients treated
at time of PET scanning; 1: prednisone monotherapy; 2: methotrexate monotherapy; 3: prednisone and methotrexate combination
therapy; 4: methotrexate and infliximab combination therapy; ACE: serum angiotensin-converting enzyme; sIL-2R: soluble interleukin-2
Receptor; CRP: C-reactive protein; CXR: chest X-ray; FVC: forced vital capacity; % pred: percentage of predicted values; DLCO: diffusion
capacity for carbon monoxide; RFI: respiratory functional impairment, defined as present if DLCO was <80%, FEV1 was <80%, or FVC was
<80% of the predicted value. p < 0.05 was considered to indicate significance.
Table 4 HRCT features of the sarcoidosis patients cate-
gorized by absence or presence of positive PET findings in
the pulmonary parenchyma.
Pulmonary
parenchyma
PET  patients
(n Z 39)
Pulmonary
parenchyma
PET þ patients
(n Z 56)
p value
Total HRCT score 3.0  2.9 7.1  3.6 <0.001
BVB score 0.4  0.7 1.3  1.1 <0.001
ND score 0.6  0.7 1.3  0.9 <0.001
LS score 0.3  0.5 0.8  0.8 0.001
PC score 0.4  0.6 1.0  0.8 0.001
PL score 0.5  0.8 1.3  1.0 <0.001
LN score 0.8  1.1 1.5  0.9 0.002
Fibrosis on HRCT 4 (10%) 22 (39%) 0.002
Data are presented as mean  SD; absolute numbers or
percentages if appropriate. PET: positron emission tomography;
-: negative; þ: positive; n:number; HRCT: high-resolution
computed tomography (HRCT); BVB: thickening or irregularity
of the bronchovascular bundle; PC: parenchymal consolidation
(including groundglass opacifications); ND: intraparenchymal
nodules; LS: septal and nonseptal lines; PL: focal pleural
thickening; LN: enlargement of the mediastinal lymph nodes.
p < 0.05 was considered to indicate significance.
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Figure 1 ROC curve of the association between the total
HRCT score and positive PET results. AUC 0.81, C.I. 0.73e0.90.
444 R.L.M. Mostard et al.PET-positivity (79  16% predicted; p Z 0.001). The
predictive value for PET-positivity of a model based on lung
function parameters expressed by the AUC was for FVC and
DLCO 0.62 (CI 0.49e0.74) and 0.73 (CI 0.60e0.83),
respectively. All patients with DLCO<45% (n Z 8) or
FVC<50% (n Z 3) showed positive pulmonary PET findings.Figure 2 Example of pulmonary PET-positivity in a 45-year-
old female sarcoidosis patient with fibrotic changes on HRCT.
The transversal PET/CT fusion image at thoracic level (upper
image) shows areas of FDG accumulation bilateral in the hilar
regions and in several mediastinal lymph nodes. The HRCT
image (lower image) at the same level shows architectural
parenchymal distortion with parenchymal opacities, thickening
and irregularity of the bronchovascular bundle, irregular
pleural thickening and in the left lung a limited area ofDiscussion
In this study, we demonstrated that the severity of
pulmonary involvement as assessed by HRCT features and
lung function parameters is associated with pulmonary PET
activity in sarcoidosis. Remarkably, inflammatory activity
appeared to be present in the majority of patients with
signs of fibrosis on HRCT.honeycombing.
Table 5 Area under the curve (AUC) values for the asso-
ciation between positive pulmonary parenchymal results
and the different HRCT patterns as included in the HRCT
score.
AUC Confidence interval
BVB 0.75 0.65e0.85
ND 0.72 0.61e0.82
LS 0.68 0.58e0.79
PC 0.75 0.58e0.80
PL 0.68 0.65e0.85
LN 0.81 0.57e0.80
AUC: area under the curve; HRCT: high-resolution computed
tomography; BVB: thickening or irregularity of the broncho-
vascular bundle; PC: parenchymal consolidation (including
groundglass opacifications); ND: intraparenchymal nodules; LS:
septal and nonseptal lines; PL: focal pleural thickening; LN:
enlargement of the mediastinal lymph nodes.HRCT features and PET findings
All HRCT features included in the used HRCT scoring system
were associated with pulmonary PET-positivity. Previous
follow-up CT studies in patients with pulmonary sarcoidosis
have shown that nodular opacities represent potentially
reversible findings, and thus the presence of inflammatory
activity in these nodules could be expected.24,25 However,
the use of HRCT findings to identify the presence of residual
active, reversible lesions in a background of fibrosis is much
more difficult. The previously mentioned follow-up CT scan
studies showed that cystic air spaces and architectural
distortion are irreversible findings, with or without treat-
ment.24,25 Based on the results of the present study, these
latter findings do not exclude the presence of associated
potentially reversible pulmonary parenchymal lesions,
though. The used HRCT scoring system was criticized in the
past because of the lack of an included fibrosis score.6
Pulmonary involvement and PET activity in sarcoidosis 445Therefore, in the present study the presence of signs of
fibrosis on HRCT was scored separately. The majority of
patients with signs of fibrosis on HRCT and CXR had positive
pulmonary PET findings. Increased FDG uptake has also
been observed in patients with idiopathic pulmonary
fibrosis (IPF).26e29 All of the models proposed for the
pathogenesis of pulmonary fibrosis involve a central role for
fibroblasts, which are known to express glucose trans-
porter-1.27,30 It is tempting to speculate that the elevated
FDG uptake in patients with fibrotic changes, including
honeycombing, might be a reflection of increased fibroblast
metabolism and not due to inflammatory activity sensu
strictu. In contrast to IPF patients, the majority of the
pulmonary PET-positive sarcoidosis patients with fibrosis on
HRCT in our population showed extrathoracic PET-positive
findings (82%) and increased serological inflammatory
markers (73%). Furthermore, mean SUVmax (7.1  3.6) in
these patients was higher than reported by two studies with
IPF patients26,27 (0.99  0.29 and 2.9  1.1, respectively).
These findings strongly suggest that PET-positive findings in
sarcoidosis patients with CXR stage IV are indeed related to
inflammatory activity.
Deciding which sarcoidosis patients with pulmonary
fibrosis may benefit from pharmacological treatment
remains a challenge to clinicians, as it is not always clear
whether respiratory symptoms in these patients are a result
of organ damage or due to ongoing inflammation or both.
Careful consideration also needs to be given to the likely
benefits of any therapy, set against the risk of adverse
events, since adding the burden of medication like corti-
costeroids to these disabled patients might harm them even
further. To date, there is no medication with the capability
of reversing fibrosis, but there is hope that treatment can
arrest fibrosis of reversible granulomas that persist among
the fibrotic elements.31 This is in line with the results of the
post-hoc analysis in the Sarcoidosis Investigators study,
which suggested a greater benefit of infliximab therapy in
patients with more severe disease, including radiographic
stage IV.32 Techniques that are purported to differentiate
fibrotic tissue from granulomatous tissue with inflammatory
activity are therefore of importance. There is little
evidence to support corticosteroid or immunosuppressive
treatment of fibrotic lung disease unless the presence of
inflammatory activity can be demonstrated.31
Several reports have demonstrated a significant reduc-
tion of FDG uptake after the initiation or modification of
treatment in sarcoidosis patients.16,18,33e35 Keijsers et al.33
demonstrated that changes in PET-imaging in a small cohort
of sarcoidosis patients treated with infliximab considerably
correlated with clinical signs of improvement. Another
study showed that diffuse pulmonary parenchymal activity
in sarcoidosis patients, as imaged by 18F-FDG PET, pre-
dicted a future deterioration of DLCO when medical
treatment was withheld, while treatment with corticoste-
roids or immunosuppressive drugs significantly improved
lung function.36 Teirstein et al.18 described that the
improvement of symptoms, conventional imaging findings,
and physiological data paralleled the therapy-related
decrease in SUVmax as seen on the PET scans in most
patients, including three patients with radiographic stage
IV. Although the exact importance of the presence of
inflammatory activity for treatment decisions obviouslyneeds to be established in future prospective, longitudinal
studies, the above-mentioned findings support the clinical
and therapeutic relevance of positive PET findings in
sarcoidosis. Moreover, the detection of PET-positive extra-
thoracic lesions can be helpful to differentiate between
sarcoidosis and other ild like IPF in patients presenting with
pulmonary fibrosis.
HRCT appeared to be superior to CXR for presuming
positive pulmonary PET findings because pulmonary PET-
positivity was assessed or excluded with specific values of
the total HRCT score (in case of respectively >10 and
0 points). A positive relation was found between pulmonary
positive PET findings and higher CXR stages, however, CXR
stage 0 did not exclude positive pulmonary PET findings
(27% had positive pulmonary PET findings) and a minority of
patients (12%) with CXR stage IV had negative pulmonary
PET findings. These results confirm the results of previous
studies that in individual cases radiographic findings as such
hardly discriminate between ongoing activity and end-stage
fibrotic lesions.37,38 HRCT findings, however, appeared to
be useful in distinguishing between inflammatory activity
and irreversible fibrosis. HRCT can reveal abnormalities
beyond the detection limits of a CXR. For example, HRCT is
superior to chest radiography in detecting nodules,
enlargement of the mediastinal lymph nodes, pleural
thickening, (non)septal lines and thickening or irregularity
of the bronchovascular bundle.6,37e39 Since all of the HRCT
patterns included in the used semiquantitative scoring
system were associated with positive PET findings in the
pulmonary parenchyma (Table 4), the detection of all these
features seems to be of importance and this underlines the
value of HRCT scanning in the assessment of inflammatory
activity in sarcoidosis. It should be noted that although all
patients with a total HRCT score of 0 points (n Z 11) had
negative pulmonary PET findings, five of them demon-
strated extrathoracic positive PET findings. The question
can be raised which patients might benefit from having
a PET scan. Previously, it was demonstrated that PET
appeared to offer added value in assessing inflammatory
activity in sarcoidosis patients with unexplained persistent
disabling symptoms in the absence of serological signs of
inflammation.19 This warrants the use of other diagnostic
tools like PET for assessment of inflammatory activity in
patients with persistent disabling symptoms in the absence
of lung functional deterioration or serological signs of
inflammatory activity and with no or limited (total HRCT
score <10) radiologic abnormalities. Recently, a clinical
prediction rule, based on sIL-2R results and HRCT results,
was developed and appeared to be useful to identify
sarcoidosis patients with a high probability of inflammatory
activity.40 Hence, using this rule may be helpful to identify
sarcoidosis patients in whom PET might be of additional
value to assess inflammatory activity.Lung function and PET findings
The relationship between respiratory functional impair-
ment and morphological abnormalities on HRCT is well
established in sarcoidosis patients.6,12,23,41 In clinical
practice, impaired, but unchanging lung function is often
regarded as disease in remission without indication for
446 R.L.M. Mostard et al.treatment. However, the present study demonstrated
a relationship between impaired lung function and pulmo-
nary PET-positivity. This is in accordance with the above-
mentioned study of Keijsers et al.36 and with a study in
a population of patients with mixed interstitial lung
disease.27 The disabled patients with impaired lung func-
tion and pulmonary PET-positivity might benefit from
treatment. Keijsers et al.36 demonstrated that the pres-
ence of inflammatory activity in the pulmonary parenchyma
is associated with an improvement of lung function after
therapy in patients with impaired lung function.
In the present study, PET-positivity was demonstrated in
all patients with a DLCO<45% or FVC<50%. Further studies
are required to prove whereas these values can be adopted
as threshold for clinical use.
This study has several limitations. First, the study pop-
ulation was gathered in a referral centre for sarcoidosis, so
the refractory character of the disease may have been
more severe than in a general sarcoidosis population.
Follow-up of the patients was generally performed by their
own physicians and therefore no standardized follow-up
data were available for analysis. Second, histological
diagnosis was not available in a minority of the studied
patients. However, in these patients, a reliable diagnosis
could be made based on consistent clinical features and
bronchoalveolar fluid analysis in accordance with the
WASOG guidelines. Part of these patients initially presented
with Lo¨fgren’s syndrome and it is generally accepted that
histological evidence is not necessary in those patients.1
Third, HRCT and PET were not performed in every
referred patient, since only part of the patients was
referred because of unexplained persistent disease related
symptoms. This might cause a selection bias. The questions
asked by the referring physicians and the reasons for
referring the patients to our centre were very diverse and
these investigations were not necessary in all patients to
answer the questions appropriately. However, this does not
mean that these patients had less severe sarcoidosis.
In conclusion, the severity of pulmonary involvement as
assessed by HRCT features and lung function parameters
was associated with increased PET activity in sarcoidosis.
Interestingly, inflammatory activity was demonstrated by
positive PET findings, next to pulmonary also extrathoracic
(82%), as well as by serological signs of inflammatory
activity (73%) in the majority (85%) of patients with radio-
logical fibrotic changes.Conflict of interest
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